The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Castle Biosciences Inc shares valued at $94,851 were sold by MAETZOLD DEREK J on Apr 21 ’25. At $21.52 per share, MAETZOLD DEREK J sold 4,408 shares. The insider’s holdings dropped to 4,275 shares worth approximately $80455.5 following the completion of this transaction.
Also, MAETZOLD DEREK J sold 1,236 shares, netting a total of over 26,596 in proceeds. Following the sale of shares at $21.52 each, the insider now holds 74,627 shares.
Before that, MAETZOLD DEREK J had sold 3,647 shares from its account. In a trade valued at $73,739, the Pres. & Chief Exec. Officer traded Castle Biosciences Inc shares for $20.22 each. Upon closing the transaction, the insider’s holdings decreased to 3,647 shares, worth approximately $83560.8.
As published in their initiating research note from Guggenheim on December 14, 2023, Castle Biosciences Inc [CSTL] has been a Buy and the price target has been revised to $25. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in early January. As of January 07, 2022, Stephens has initiated its “an Overweight” rating for CSTL. Earlier on April 30, 2021, Lake Street initiated its rating. Their recommendation was “a Buy” for CSTL stock.
Analyzing CSTL Stock Performance
During the last five days, there has been a surge of approximately 10.58%. Over the course of the year, Castle Biosciences Inc shares have dropped approximately -29.38%. Shares of the company reached a 52-week high of $32.74 on 01/08/25 and a 52-week low of $15.45 on 05/28/25.
Support And Resistance Levels for Castle Biosciences Inc (CSTL)
According to the 24-hour chart, there is a support level at 18.38, which, if violated, would cause prices to drop to 17.95. In the upper region, resistance lies at 19.04. The next price resistance is at 19.27. RSI (Relative Strength Index) is 63.87 on the 14-day chart, showing neutral technical sentiment.
